Mr. Tyler Robson reports

VALENS ANNOUNCES STRATEGIC SECONDARY PURCHASE AND SALE TRANSACTION

Valens Groworks Corp. has provided a news release for a strategic secondary purchase and sale transaction.

The transaction includes a total of 3.5 million shares at a price of $2.05 per share between strategic purchasers (the buyers) and 1009638 B.C. Ltd. (the seller). The buyers are independent in nature as they are not directly associated with a third party licensed producer. On close of the transaction, the seller hereby represents that it continues to be a significant shareholder of the company and has opted to lock up the remaining shares they hold in Valens for six months showing its long-term commitment to the company. The buyers will also lock up shares for a period of four months on close of the transaction. AltaCorp Capital Inc. has acted as agent in the transaction.

"We are excited to announce the strategic secondary purchase and sale transaction with key institutions and shareholders," said Tyler Robson, chief executive officer of Valens Groworks. "We are appreciative of our largest shareholder's continued commitment to the long-term vision and strategy of the company and welcome our new strategic shareholders."

About Valens Groworks Corp.

Valens Groworks is a research-driven, vertically integrated Canadian cannabis company focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification, as well as associated quality testing with three wholly owned subsidiaries, located in and around Kelowna, B.C. Subsidiary Valens Agritech (VAL) holds a licence to cultivate cannabis and produce cannabis oil under the Cannabis Act, as well as a licence to conduct analytical testing for the cannabis industry. Subsidiary Valens Labs is a Health Canada-licensed ISO 17025-accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a centre of excellence in plant-based science. Subsidiary Valens Farms is in the process of becoming a purpose-built facility in compliance with European Union (EU) Good Manufacturing Practices (GMP) standards, ensuring the product from this facility can be exported anywhere in the world where cannabis is nationally legal for medical or adult-usage purposes.

We seek Safe Harbor.